Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
InMatrico is a platform of decellularized extracellular matrix (dECM) products developed by Xylyx Bio for use in tissue engineering and regenerative medicine. These biologic scaffolds are produced through a proprietary process that removes cellular components from native tissues while preserving the essential biochemical composition and structural architecture of the extracellular matrix. By mimicking the natural microenvironment, InMatrico supports cell adhesion, proliferation, and organized tissue growth. It is intended for surgical implantation or as a framework for bioengineered tissues to facilitate the repair and regeneration of damaged organs and tissues.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on InMatrico.